Efficacity of Idelalisib and Obinutuzumab in Patient With Relapsed Refractory Waldenstrom's Macroglobulinemia

NCT02962401 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Waldenstrom Macroglobulinemia

Interventions

DRUG: Obinutuzumab
DRUG: Idelalisib

Sponsor

French Innovative Leukemia Organisation